Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors.
Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Rotz SJ, Fraint E, Rangarajan HG, Auletta JJ, Sharma A, Kitko CL, Hashem H, Williams KM, Wirk B, Dvorak CC, Myers KC, Pulsipher MA, Warwick AB, Lalefar NR, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA.
Knight TE, et al. Among authors: wall da.
Transplant Cell Ther. 2023 Jun;29(6):380.e1-380.e9. doi: 10.1016/j.jtct.2023.03.024. Epub 2023 Mar 27.
Transplant Cell Ther. 2023.
PMID: 36990222
Free PMC article.
Stratification of CD34(+) dose by quartile did not reveal any statistically significant differences between quartiles for 3-year PFS (p = .66), OS (p = .29), risk of relapse (p = .57), or EIC (p = .87). ...Children with medulloblastoma had superior PFS …
Stratification of CD34(+) dose by quartile did not reveal any statistically significant differences between quartiles for 3-year PFS (p …